This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research .

Poster presentation

Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma

P Lu¹, C Yang¹, I Guasparri¹, W Harrington², YL Wang¹, E Cesarman¹ and the AIDS Malignancy Clinical Trials Consortium

¹  Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA

²  The Viral Oncology Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, USA

corresponding author email

from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Bethesda, MD, USA. 6–7 October 2008

Infectious Agents and Cancer 2009, 4(Suppl 2):P13doi:10.1186/1750-9378-4-S2-P13

Published:	17 June 2009

First paragraph (this article has no abstract)

We have evaluated whether targeting the Src family kinase cascade, an early component of B-cell receptor (BCR) signaling, is an effective strategy to treat AIDS-related lymphoma (ARL). Src kinases are activated after ligation of the BCR and they phosphorylate downstream signaling proteins in tyrosine residues relaying B-cell signaling cascades that lead to B cell activation and proliferation. These kinases play an important role in lymphoma pathogenesis. We have shown that Src kinases are constitutively active in diffuse large cell lymphoma (DLBCL) cells occurring in immunocompetent individuals and inhibition of these kinases using dasatinib inhibits proliferation of the lymphoma cells.